[1]
Wenzel SE,Kamada AK, Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma. The Annals of pharmacotherapy. 1996 Jul-Aug;
[PubMed PMID: 8826571]
[2]
Lee SE,Farquhar DR,Adams KN,Masood MM,Senior BA,Thorp BD,Zanation AM,Ebert CS, Effect of Zileuton Treatment on Sinonasal Quality of Life in Patients with Aspirin-Exacerbated Respiratory Disease. American journal of rhinology
[PubMed PMID: 31483687]
Level 2 (mid-level) evidence
[3]
Berger W,De Chandt MT,Cairns CB, Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease. International journal of clinical practice. 2007 Apr;
[PubMed PMID: 17394438]
[4]
Dolinska M,Piccini A,Wong WM,Gelali E,Johansson AS,Klang J,Xiao P,Yektaei-Karin E,Strömberg UO,Mustjoki S,Stenke L,Ekblom M,Qian H, Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34{sup} {/sup}CD38{sup}-{/sup} stem and progenitor cells in chronic myeloid leukemia. Biochemical and biophysical research communications. 2017 Aug 19;
[PubMed PMID: 28623130]
Level 2 (mid-level) evidence
[5]
Makary CA,Holmes T,Unsal A,Munjal A,Ryan L,Reyes C,Kountakis SE, Long-term role of zileuton in the treatment of chronic rhinosinusitis in aspirin exacerbated respiratory disease. American journal of otolaryngology. 2022 Jan-Feb;
[PubMed PMID: 34563805]
[6]
Laidlaw TM, Clinical updates in aspirin-exacerbated respiratory disease. Allergy and asthma proceedings. 2019 Jan 1;
[PubMed PMID: 30582489]
[8]
Shameera Ahamed TK,Rajan VK,Sabira K,Muraleedharan K, QSAR classification-based virtual screening followed by molecular docking studies for identification of potential inhibitors of 5-lipoxygenase. Computational biology and chemistry. 2018 Dec;
[PubMed PMID: 30321850]
[9]
Dahlin A,Qiu W,Litonjua AA,Lima JJ,Tamari M,Kubo M,Irvin CG,Peters SP,Wu AC,Weiss ST,Tantisira KG, The phosphatidylinositide 3-kinase (PI3K) signaling pathway is a determinant of zileuton response in adults with asthma. The pharmacogenomics journal. 2018 Sep
[PubMed PMID: 29298996]
Level 2 (mid-level) evidence
[10]
Morina N,Boçari G,Iljazi A,Hyseini K,Halac G, Maximum Time of the Effect of Antileukotriene - Zileuton in Treatment of Patients with Bronchial Asthma. Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH. 2016 Feb
[PubMed PMID: 27046942]
[11]
Nelson H,Kemp J,Berger W,Corren J,Casale T,Dube L,Walton-Bowen K,LaVallee N,Stepanians M, Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study. Annals of allergy, asthma
[PubMed PMID: 17718106]
Level 1 (high-level) evidence
[13]
Thalanayar Muthukrishnan P,Nouraie M,Parikh A,Holguin F, Zileuton use and phenotypic features in asthma. Pulmonary pharmacology & therapeutics. 2020 Feb
[PubMed PMID: 31841698]
[14]
Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, Cruz AA, Duijts L, Drazen JM, FitzGerald JM, Fleming LJ, Inoue H, Ko FW, Krishnan JA, Levy ML, Lin J, Mortimer K, Pitrez PM, Sheikh A, Yorgancioglu AA, Boulet LP. Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. American journal of respiratory and critical care medicine. 2022 Jan 1:205(1):17-35. doi: 10.1164/rccm.202109-2205PP. Epub
[PubMed PMID: 34658302]
[15]
Popa M,Peltecu G,Gica N,Ciobanu AM,Botezatu R,Gica C,Steriade A,Panaitescu AM, Asthma in Pregnancy. Review of Current Literature and Recommendations. Maedica. 2021 Mar;
[PubMed PMID: 34221160]
[16]
Namazy J,Schatz M, The Treatment of Allergic Respiratory Disease During Pregnancy. Journal of investigational allergology & clinical immunology. 2016
[PubMed PMID: 27012010]
[18]
Yanes DA,Mosser-Goldfarb JL, Emerging therapies for atopic dermatitis: The prostaglandin/leukotriene pathway. Journal of the American Academy of Dermatology. 2018 Mar;
[PubMed PMID: 29248523]
[19]
Bruno F,Spaziano G,Liparulo A,Roviezzo F,Nabavi SM,Sureda A,Filosa R,D'Agostino B, Recent advances in the search for novel 5-lipoxygenase inhibitors for the treatment of asthma. European journal of medicinal chemistry. 2018 Jun 10;
[PubMed PMID: 29133059]
Level 3 (low-level) evidence
[20]
Wenzel S,Busse W,Calhoun W,Panettieri R Jr,Peters-Golden M,Dube L,Walton-Bowen K,Russell H,Harris J, The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma: a 6-month randomized controlled study. The Journal of asthma : official journal of the Association for the Care of Asthma. 2007 May
[PubMed PMID: 17530530]
Level 1 (high-level) evidence
[21]
Lorenzetti F,Vera MC,Ceballos MP,Ronco MT,Pisani GB,Monti JA,Lucci A,Comanzo CG,Tordjmann T,Carrillo MC,Quiroga AD,Alvarez ML, Participation of 5-lipoxygenase and LTB4 in liver regeneration after partial hepatectomy. Scientific reports. 2019 Dec 3;
[PubMed PMID: 31796842]
[22]
Gross N,Greos LS,Meltzer EO,Spangenthal S,Fishman RS,Spyker DA,Cassella JV, Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease--two randomized controlled trials. Journal of aerosol medicine and pulmonary drug delivery. 2014 Dec
[PubMed PMID: 24745666]
Level 1 (high-level) evidence
[23]
Villa-Zapata L, Gómez-Lumbreras A, Horn J, Tan MS, Boyce RD, Malone DC. A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS). Drug safety. 2022 Aug:45(8):863-871. doi: 10.1007/s40264-022-01200-4. Epub 2022 Jul 14
[PubMed PMID: 35834155]
[24]
Awni WM,Hussein Z,Granneman GR,Patterson KJ,Dubé LM,Cavanaugh JH, Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans. Clinical pharmacokinetics. 1995;
[PubMed PMID: 8620673]
[25]
Lu P,Schrag ML,Slaughter DE,Raab CE,Shou M,Rodrigues AD, Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug metabolism and disposition: the biological fate of chemicals. 2003 Nov;
[PubMed PMID: 14570767]
[26]
Granneman GR,Braeckman RA,Locke CS,Cavanaugh JH,Dubé LM,Awni WM, Effect of zileuton on theophylline pharmacokinetics. Clinical pharmacokinetics. 1995;
[PubMed PMID: 8620674]
[27]
Cingi C,Muluk NB,Ipci K,Şahin E, Antileukotrienes in upper airway inflammatory diseases. Current allergy and asthma reports. 2015 Nov;
[PubMed PMID: 26385352]
[29]
Powrie RO,Larson L,Miller M, Managing asthma in expectant mothers. Treatments in respiratory medicine. 2006;
[PubMed PMID: 16409012]
[30]
Watkins PB,Dube LM,Walton-Bowen K,Cameron CM,Kasten LE, Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma. Drug safety. 2007;
[PubMed PMID: 17722971]
[31]
Gallucci M,Carbonara P,Pacilli AMG,di Palmo E,Ricci G,Nava S, Use of Symptoms Scores, Spirometry, and Other Pulmonary Function Testing for Asthma Monitoring. Frontiers in pediatrics. 2019
[PubMed PMID: 30891435]
[32]
Peak flow meter use in asthma management. Thoracic Society of Australia and New Zealand. The Medical journal of Australia. 1996 Jun 17
[PubMed PMID: 8668080]
[33]
Buzoianu E,Moiceanu M,Plesca DA, Asthma Control Assessment in Children: Correlation between Asthma Control Test and Peak Expiratory Flow. Maedica. 2014 Dec
[PubMed PMID: 25705302]
[35]
Gummin DD,Mowry JB,Beuhler MC,Spyker DA,Brooks DE,Dibert KW,Rivers LJ,Pham NPT,Ryan ML, 2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report. Clinical toxicology (Philadelphia, Pa.). 2020 Dec
[PubMed PMID: 33305966]
[36]
National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases, Science Brief: Evidence Used to Update the List of Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19 CDC COVID-19 Science Briefs. 2020
[PubMed PMID: 34009770]
[37]
Morrison D,Wyke S,Saunderson K,McConnachie A,Agur K,Chaudhuri R,Thomas M,Thomson NC,Yardley L,Mair FS, Findings from a pilot Randomised trial of an Asthma Internet Self-management Intervention (RAISIN). BMJ open. 2016 May 12;
[PubMed PMID: 27173807]
Level 3 (low-level) evidence